SCHEMBL650754

SCHEMBL650754

O=S(=O)(NC1Cc2cc(-c3ccc(F)cc3)ccc2N(Cc2ccccc2)C1)c1ccc(-c2ccon2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.47
F10 P00742 5/20 0.44
F2 P00734 2/20 0.38
MMP8 P22894 4/20 0.38
MMP3 P08254 2/20 0.38
PFKFB3 Q16875 1/20 0.37
FNTA P49354 1/20 0.36
FNTB P49356 1/20 0.36
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
MTNR1A P48039 1/20 0.34
MTNR1B P49286 1/20 0.34
ALDH1A1 P00352 2/20 0.33
POLB P06746 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MAPT P10636 1/20 0.33
PPARG P37231 1/20 0.33
LMNA P02545 1/20 0.33
PKM P14618 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650432 0.85 FNTA (0.38) NR1H2F10F2PFKFB3FNTA
SCHEMBL651298 0.85 PSEN1 (0.43) F10FNTAFNTBKMT2AMTNR1A
SCHEMBL651273 0.80 FNTA (0.49) NR1H2FNTAFNTBKMT2AMEN1
SCHEMBL651315 0.80 FNTA (0.49) NR1H2FNTAFNTBKMT2AMEN1
SCHEMBL651274 0.80 FNTA (0.49) NR1H2FNTAFNTBKMT2AMEN1
SCHEMBL651439 0.79 FNTA (0.44) NR1H2F10FNTAFNTBKMT2A
SCHEMBL651571 0.77 FNTA (0.40) FNTAFNTBKMT2AMEN1MTNR1A
SCHEMBL654189 0.77 NR1H2 (0.44) NR1H2FNTAFNTBMTNR1AMTNR1B
SCHEMBL649304 0.77 FNTA (0.45) NR1H2F10FNTAFNTBKMT2A
SCHEMBL650258 0.77 MTNR1A (0.42) NR1H2F10F2FNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119808-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-21 US claimed
US-20110104315-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2011-05-05 US claimed
US-20050014786-A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY 2005-01-20 US claimed
US-8119808-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-21 US disclosed
US-20110104315-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2011-05-05 US disclosed
US-7884113-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-08 US disclosed
US-20080194625-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2008-08-14 US disclosed
US-20050014786-A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110104315-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, OPRL1 NR1H2 85/4885F10 3174/4885F2 1331/4885
US-20050014786-A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators CNR2, CNR1, OPRL1 NR1H2 85/4885F10 3174/4885F2 1331/4885
US-20080194625-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, OPRL1 NR1H2 85/4885F10 3174/4885F2 1331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.